Details of the Drug
General Information of Drug (ID: DMCM5GK)
| Drug Name |
TAK-070
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
UNII-PNM9E64544; PNM9E64544; TAK-070; (2R)-N,N-Dimethyl-6-(4-biphenylylmethoxy)-1,2,3,4-tetrahydronaphthalene-2alpha-ethanamine; TAK-070 free base; N,N-dimethyl-2-[(2R)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine; N,N-Dimethyl-2-((2R)-6-((4-phenylphenyl)methoxy)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine; SCHEMBL361018; GTPL6940; 212571-56-7; J3.229.705F; 2-((2R)-6-(4-Biphenylylmethoxy)-1,2,3,4-tetrahydro-2-naphthalenyl)-N,N-dimethylethanamine; 2-Naphthaleneethanamine, 6-((1,1'-biphenyl)-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 |
Molecular Weight | 440 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
| Rotatable Bond Count | 7 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Solid tumour/cancer | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 2A00-2F9Z | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


